Compare Midsona AB with Similar Stocks
Dashboard
1
With a growth in Net Profit of 73.68%, the company declared Very Positive results in Dec 25
- The company has declared positive results for the last 7 consecutive quarters
- RAW MATERIAL COST(Y) Fallen by 1.11% (YoY)
- CASH AND EQV(HY) Highest at SEK 509 MM
- DEBT-EQUITY RATIO (HY) Lowest at 10.19 %
2
With ROE of 1.26%, it has a very attractive valuation with a 0.39 Price to Book Value
3
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,716 Million (Small Cap)
31.00
NA
10.14%
0.10
2.64%
0.58
Revenue and Profits:
Net Sales:
933 Million
(Quarterly Results - Dec 2025)
Net Profit:
33 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
37.5%
0%
37.5%
6 Months
45.78%
0%
45.78%
1 Year
38.76%
0%
38.76%
2 Years
53.75%
0%
53.75%
3 Years
-46.93%
0%
-46.93%
4 Years
-82.96%
0%
-82.96%
5 Years
-77.63%
0%
-77.63%
Midsona AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.43%
EBIT Growth (5y)
-10.70%
EBIT to Interest (avg)
1.16
Debt to EBITDA (avg)
3.47
Net Debt to Equity (avg)
0.14
Sales to Capital Employed (avg)
1.03
Tax Ratio
41.54%
Dividend Payout Ratio
319.77%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.63%
ROE (avg)
2.09%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
0.39
EV to EBIT
14.44
EV to EBITDA
6.14
EV to Capital Employed
0.47
EV to Sales
0.44
PEG Ratio
0.34
Dividend Yield
15.05%
ROCE (Latest)
3.25%
ROE (Latest)
1.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
933.00
961.00
-2.91%
Operating Profit (PBDIT) excl Other Income
82.00
75.00
9.33%
Interest
8.00
13.00
-38.46%
Exceptional Items
-5.00
0.00
Consolidate Net Profit
33.00
19.00
73.68%
Operating Profit Margin (Excl OI)
51.40%
38.50%
1.29%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -2.91% vs -4.19% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 73.68% vs 533.33% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,630.00
3,727.00
-2.60%
Operating Profit (PBDIT) excl Other Income
276.00
281.00
-1.78%
Interest
39.00
58.00
-32.76%
Exceptional Items
-74.00
0.00
Consolidate Net Profit
10.00
47.00
-78.72%
Operating Profit Margin (Excl OI)
36.90%
34.60%
0.23%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -2.60% vs -1.74% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -78.72% vs 188.68% in Dec 2024
About Midsona AB 
Midsona AB
Pharmaceuticals & Biotechnology
Midsona AB, formerly Midelfart Sonesson AB is a Sweden-based company engaged in the development, manufacture and marketing of consumer healthcare products in the Nordic region. Its products are divided into three product areas: Healthfoods, Hygiene, Personal Care. The Company consists of three geographical areas, namely Sweden, Norway and Finland. The business areas in Sweden, Norway and Finland market and sell nutritional supplements, herbal remedies, health foods, skin care and beauty products to grocery stores, pharmacies and health stores in respective geographic markets. The Company has several priority brands, such as Friggs, Urtekram, Naturdiet, Miwana, MyggA, Dalblads, Tri Tolonen, Supernature.
Company Coordinates 
Company Details
Dockplatsen 16, Box 21009 , MALMO None : 200 21
Registrar Details






